EUVIMEDObjevte EUVIMED
CrossrefInformační karta

The Evolving Landscape of Continuous Glucose Monitoring Metrics in Type 1 Diabetes: Narrative Literature Review

Eric Williams Jr, Casey Rand, Alessandra Ayers, Cindy Ho, Ashley Dunova, David Klonoff, Juan Espinoza

JMIR Diabetes · 2026-07-23 · 11 · e92455-e92455

DOI: 10.2196/92455 ↗
AbstraktBibliografické údaje

Abstrakt

Abstract Background Continuous glucose monitoring (CGM) has transformed diabetes management and research by providing high-frequency data that address many of the limitations of hemoglobin A 1c , enabling more precise clinical treatment targets and responsive trial endpoints. The richness and complexity of high-resolution time-series CGM data have spurred the development of numerous metrics for both clinical care and research applications. Beyond established metrics, there is a growing set of clinical, composite, and research-oriented measures that may support clinical decision support, intervention planning, risk stratification, and discovery-oriented research. This proliferation has created significant challenges in metric selection, interpretation, calculation, and standardization, particularly when metrics are applied across different devices, populations, software packages, and study designs. Objective The objective is to map the current landscape of CGM metrics and address ongoing challenges in metric selection, clinical and research interpretation, and standardization. We further sought to distinguish between metrics primarily suited for routine clinical interpretation and those designed to explore more granular or multidimensional features of glycemia in research settings. Methods We identified the literature focusing on the calculation, application, and interpretation of the following categories of CGM metrics: (1) standardized, (2) clinical, (3) emerging, and (4) composite. CGM metrics included in this study were identified from the 27 metrics included in the Diabetes Research Hub platform, additional published standardized and composite metrics, metrics used in established CGM analysis software, and emerging metrics identified during review. We narratively reviewed each metric’s definitions, calculation methods, interpretation, clinical and research utility, and strengths and limitations. In total, 102 articles were reviewed, supporting the synthesis of 36 distinct CGM-derived metrics. Results The review identifies a fundamental divide in the CGM metric landscape. Standardized and clinical metrics, including time in range, mean glucose, coefficient of variation, and similar, prioritize simplicity and actionability. These metrics facilitate rapid decision-making in clinical settings but potentially mask granular glycemic fluctuations, event patterns, and discordance between average glucose values and variability. Emerging and composite metrics offer deeper insights into glycemic patterns, risk, and variability. However, many rely on specialized software or complex formulas, lack standardized thresholds or clear relationships to clinical outcomes, and do not have consensus methods of calculation and interpretation, limiting their adoption and hindering cross-study comparison. Conclusions While consensus exists for core clinical metrics, the lack of standardization for complex metrics hinders research replicability and clinical translation. Bridging this gap requires moving toward consensus metric definitions, open-science frameworks, and standardized code libraries. Metric selection should be guided by intended use. Clinical metrics should be well-established, interpretable, and actionable. Research metrics should be clearly described, reproducible, and linked to meaningful outcomes. This review provides a comprehensive resource for navigating the diverse spectrum of CGM metrics, clarifying their applications and limitations to support both research and clinical investigation.

Znalosti, které odpovídají vaší práci.

Od bezplatného začátku přes osobní rešerše literatury až po kompletní Research Suite.

Zobrazit tarify →

Jsou zahrnuty všechny plné texty vydavatelů?

Ne. Bibliografické záznamy, abstrakty a plné texty jsou různé typy obsahu. To, zda je plný text dostupný, závisí na zdroji, Open Access a vašich stávajících licencích. Tarif EUVIMED nenahrazuje dodatečná vydavatelská práva.

Zobrazit tarify →